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CRP R2 5 0.74, and FABP R2 5 0.70).
Discussion: The current findings highlight the importance of considering blood fractions and assay
platforms when searching for AD relevant biomarkers.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Despite tremendous scientific advancements, there re-
mains a significant concern regarding the lack of reproduc-
ibility of research findings [1–4] with most believing that
“at least 50%” of academic findings will not be replicable
within industry laboratories [4]. In fact, the National Insti-
tutes of Health recently highlighted this problem and out-
lined a plan to address the issue [2]. In recent years, there
has been an explosion in the search for blood-based bio-
markers related to Alzheimer’s disease (AD) for a variety
of functions, such as detection, diagnosis, risk estimation,
as well as clinical trial enrichment, stratification, and treat-
ment response. However, this work has not been immune to
the problem of replicability as conflicting findings are
commonplace in the field. In an effort to generate consistent
methods and protocols to increase replicability and
move the field of blood-based biomarkers for AD forward,
the international collaboration of the blood-based
biomarker professional interest area (BBB-PIA) of the Alz-
heimer’s Association’s International Society to Advance
Alzheimer’s Research and Treatment was formed, which
has published consensus statements regarding the current
state of the field along with most of the immediate research
needs [5,6]. More recently, the BBB-PIA published the first
ever consensus-based guidelines for preanalytic processing
for blood-based AD biomarker research [7]. The purpose of
the present study was to examine two potential sources
contributing to failures to replicate in the blood-based
biomarker field of AD, (1) blood fraction (i.e., serum vs.
plasma) and (2) analytic platform. These initiatives have
been of paramount importance and additional topics
require careful consideration.
Amajor concern for blood-based AD biomarker studies is
the selection of the most suitable blood fraction. The type of
blood fraction is important not only for the abundance of
specific analytes but also for the role of additives such
as heparin, citrate, or ethylenediaminetetraacetic acid
(EDTA), which can significantly impact both stability and
detectability of biomarkers [8,9]. However, to date, there
remains little consistency in the type of blood fraction
assayed across studies. One of the most extensively
studied plasma-based biomarkers is amyloid b (Ab), which
is one of the hallmarks of AD pathology investigated at au-topsy and is a well-validated marker of AD in cerebrospinal
fluid samples. Work by Watt et al. [10], however, highlights
many of the issues regarding plasma Ab studies. Although
some markers appear to be robust in both serum and plasma
(e.g., C-reactive protein), other markers appear to be
more robust in one fraction over the other. For example,
EDTA inhibits many proteases, which may preserve many
proteins better than serum; however, EDTA can interfere
with some mass spectrometry assays. Recent reviews on
the topic highlight the variability in blood-fraction selection
as a major contributor to inconsistent findings in blood-
based biomarker studies [11,12]. On the one hand, several
markers have been found to be significant across multiple
studies and cohorts, despite different blood fractions used
(e.g., pancreatic polypeptide [PPY] and C-reactive protein
[CRP]) [13–16]. Few studies, however, have directly
compared plasma to serum-based findings in AD. When
examining the association between serum- and plasma-
based proteomics in the Texas Alzheimer’s Research &
Care Consortium (TARCC; available at http://www.
txalzresearch.org/), a total of 40 proteins (from.100 candi-
date proteins) were highly correlated across blood fractions
(R2 0.75; 56% shared variance of proteins) [17]. In
another study using the TARCC and Alzheimer’s Disease
Neuroimaging Initiative (ADNI) data, only 11 proteins
(from .100) were highly correlated across serum and
plasma (R2 0.75) and significantly associated (P , .05)
with AD status (CRP, adiponectin, PPY, fatty acid-binding
protein [FABP], interleukin 18 [IL-18], beta 2 microglobulin
[b2M], tenascin C [TNC], I309, factor VII [FVII], soluble
vascular cell adhesion molecule-1 [sVCAM-1], and mono-
cyte chemoattractant protein-1). The serum-plasma
biomarker algorithm yielded an area under the curve
(AUC) 5 0.88 across cohorts [18]. These data suggest that
some markers are consistent across blood fraction and may
be useful for diagnostic purposes; however, others are likely
less comparable despite statistically significant correlations.
Another key issue for blood-based AD biomarker studies
is the selection of the most appropriate assay platform.Many
cohorts have used the Myriad Rules Based Medicine
(Myriad RBM) platform (e.g., ADNI, TARCC, and the
Australian Imaging, Biomarker & Lifestyle Flagship Study
of Aging) [13,14,16,18]; however, many other approaches
have been used, including the Meso Scale Discovery
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 27-34 29(MSD; available at http://www.mesoscale.com) [19] and
SOMAscan [20] multiplexed protein technologies. Recently,
several investigations have focused on identifying and vali-
dating biomarkers or biomarker algorithms across platforms
[14,19–21]; however, most studies have not attempted cross-
platform validation and others have failed to cross-validate
across platforms [22]. The use of different assay methodol-
ogies likely has substantially contributed to the inconsis-
tencies within the blood-based AD biomarker field.
The present study was undertaken to directly compare
serum- and plasma-based protein concentrations for putative
AD biomarkers as well as data obtained from the same par-
ticipants at the same blood draw using Myriad RBM versus
MSD.2. Methods
2.1. Participants2.1.1. Texas Alzheimer’s Research & Care Consortium
Nonfasting serum and plasma samples from the same
blood draw in 300 participants (150 with AD and 150 con-
trols) enrolled in the TARCC study were analyzed. Serum
samples were assayed using theMyriad RBM andMSD plat-
forms. Of the 300 samples, specimens from 144 participants
(79 with AD and 65 controls) were assayed from both serum
and plasma using the MSD platform (as described in the
following). The methodology of the TARCC protocol has
been described elsewhere [14]. Briefly, each participant
completed an annual assessment at one of the five partici-
pating sites that included a medical evaluation, neuropsy-
chological testing, a clinical interview, and a blood draw.
Diagnosis of AD dementia was based on the National Insti-
tute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria [23]; controls per-
formed within normal limits on psychometric testing (mild
cognitive impairment was not included in this study). Insti-
tutional review board approval was obtained at each site, and
written informed consent was obtained for all participants.
2.2. Human serum sample collection
TARCC samples were collected as follows: Serum—(1)
nonfasting serum samples were collected into 10-mL tiger-
top tubes; (2) samples were allowed to clot for 30 minutes
at room temperature in a vertical position; (3) samples
were centrifuged for 10 minutes at 1300! g at room tem-
perature within 1 hour of collection; (4) 1.0-mL aliquots
were transferred into cryovial tubes; (5) Freezerworks bar-
code labels were affixed to each aliquot; and (6) samples
were placed into 280C freezers for storage until use.
Plasma—(1) nonfasting blood was collected into 10-mL
lavender-top (EDTA) tubes and gently inverted 10–12 times;
(2) tubes were centrifuged at 1300! g at room temperature
for 10 minutes within 1 hour of collection; (3) 1-mL aliquotswere transferred to cryovial tubes; (4) Freezerworks barcode
labels were affixed; and (5) tubes were placed in 280C
freezers for storage.
2.3. Human assays2.3.1. Electrochemiluminescence
Plasma and serum samples were assayed in duplicate via
a multiplex biomarker assay platform using electrochemilu-
minescence (ECL) on the SECTOR Imager 2400A from
MSD (available at http://www.mesoscale.com). The MSD
platform has been used extensively to assay biomarkers
associated with a range of human diseases including AD
[24,25]. The markers assayed included FABP, b2M, PPY,
soluble tumor necrosis factor receptor 1 (sTNFR1), CRP,
VCAM-1, thrombopoietin, a2 macroglobulin, eotaxin3, tu-
mor necrosis factor-alpha (TNF-a), tenascin C (TNC), IL-
5, IL-6, IL-7, IL-10, IL-18, I309, FVII, thymus and
activation-regulated chemokine (TARC), serum amyloid A
(SAA), and intercellular cell-adhesion molecule-1. (Infor-
mation regarding assay performance, least detectable dose
(LDD), and coefficient of variation (CV) can be obtained
on request.)
2.3.2. Myriad RBM
Serum samples were shipped to Myriad RBM for assay
on the Luminex-based HumanMAP 1.0 platform. Over
100 proteins were quantified using fluorescent microspheres
with protein-specific antibodies. (Information regarding
LDD, inter-run CV, dynamic range, and overall spiked stan-
dard recovery as well as cross-reactivity with other Human-
MAP analytes are available through Myriad-RBM directly.)
2.4. Other relevant measures
Other information extracted from the database included
APOE ε4 genotype, age, gender, education, clinical demen-
tia rating scale, and mini-mental state examination (MMSE)
for demographic characterization of the sample. Variable
importance plots from random forest (RF)-generated algo-
rithms using these data in prior publications were compared
to determine the overlap of the top 10 biomarkers across
blood fraction and platforms.
2.5. Statistical analyses
Analyses were performed using IBM SPSS21. c2 and t
tests were used to compare case versus controls for categor-
ical (APOE ε4 allele frequency sex, race, dyslipidemia, dia-
betes, hypertension, and obesity) and continuous variables
(age, education, MMSE, and clinical dementia rating sum
of boxes scores [CDR-SB]), respectively. In our prior
work, we demonstrated that the serum-based proteomic pro-
file was more robust in detecting AD when compared with
plasma in this cohort using the MSD platform [19]. Here,
we compared the top 10 biomarker importance rankings
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 27-3430across serum and plasma within the same cohort. Correla-
tions across serum and plasma were conducted using Pear-
son correlations. Analyses were conducted from proteomic
data taken from the same participant at the same blood
draw only.3. Results
Compared with normal controls (NC), the AD group was
significantly older (P, .001), had fewer years of formal ed-
ucation (P , .001), and scored lower on the MMSE
(P , .001) and higher on the CDR-SB (P , .001). There
were no significant differences between groups with regard
to sex or presence of dyslipidemia, diabetes, or hyperten-
sion. The AD group included significantly more APOE ε4
carriers (Table 1). Table 2 lists means and standard devia-
tions of protein levels across blood fraction and assay plat-
forms (RBM plasma data for NCs were not available).
As listed in Table 3, nearly all the markers were statisti-
cally significantly correlated across blood fraction, only
sTNFR1, FABP, I309, IL-18, IL-10, IL-6, IL-5, PPY, eo-
taxin3, and SAA were correlated substantially high to share
at least 50% of the shared variance. However, although the
correlations were statistically significant for others, the
amount of variance shared was less than 50% for thrombopie-
tin (THPO), IL-7, TARC, TNF-a, alpha-2-macroglobulin,
b2M, FVII, CRP, TNC, soluble intercellular adhesion mole-
cule 1 (sICAM-1), and sVCAM-1. As an example, this im-
plies that approximately 44% of what was measured as
CRP in serum was similarly measured in plasma, whereas
66% of the measurement was error or something else.
Next, the variable importance plots from our previously
generated RF analyses [19] were examined (Table 4). We
previously demonstrated that the overall accuracy of the al-Table 1
Demographic characteristics of cohort
Characteristics
AD
Normal
controls
P value
(n 5 79) (n 5 65)
Mean (SD) Mean (SD)
Age (y) 76.1 (8.6) 71.2 (9.2) .002
Education (y) 14.7 (3.0) 15.5 (2.6) .02
Sex (male), % 30 32 .76
APOE ε4 presence (yes/no), % 60 23 ,.001
Hispanic ethnicity, % 3 7 .33
Race (non-Hispanic white), % 96 90 .04
MMSE 19.1 (6.4) 29.6 (0.7) ,.001
CDR-SB 7.8 (4.1) 0.0 (0.1) ,.001
Hypertension (% yes), % 54 55 .86
Dyslipidemia (% yes), % 51 40 .31
Diabetes (% yes), % 10 11 .59
Obese (% yes), % 15 14 .53
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation;MMSE,
mini-mental state examination; CDR-SB, clinical dementia rating sum of
boxes scores.gorithm using our specific profile was superior when using
serum (AUC 5 0.96) versus plasma (AUC 5 0.76) [19].
When examining the protein importance plots across serum
versus plasma, there was minimal overlap across blood frac-
tions in ranking among the top 10 biomarkers (of our 21-
protein profile). In fact, only IL-5, IL-6, and IL-7 were
consistently ranked among the top 10 biomarkers across
serum and plasma.
Next, data from 17 common markers assayed using the
MSD and RBM platforms were compared. As listed in
Table 5, 14 of the 17 correlation coefficients are statistically
significant (P , .05); however, the amount of shared vari-
ance in protein concentrations was ,50% for 12 of the 17
markers and .50% only for FABP, CRP, FVII, IL-18, and
b2M. Additionally, as listed in Table 4, only two of the top
10 markers (IL7 and TNF-a) were common among the top
10 biomarkers across the MSD and RBM platforms.4. Discussion
The current findings clearly illustrate the importance of
blood fraction and assay platform on obtained results. In
fact, our findings highlight that a blood-based algorithm
that is highly accurate in detecting AD could (and likely
would) be very different if it was conducted in serum
versus plasma or on an ECL versus a Luminex-based plat-
form. Therefore, as the science currently stands, accurate
blood-based algorithms for detecting AD likely have in-
ternal consistency only when performed on a specific
blood fraction and by a specific laboratory. Therefore, if
transition to clinical practice was the goal, the laboratory
developed test (LDT) would be the only viable option.
The international working group recently published
guidelines for processing of blood samples when con-
ducting work in the area of AD biomarkers [7]. The pre-
sent study builds on this prior work and points to the
urgent need for greater standardization if a blood-based
biomarker test is to be reliable and clinically applicable
for the detection of AD.
First, the selection of blood fraction is a nontrivial choice.
Although there have been many blood-based biomarkers of
AD identified, studies have frequently used different blood
fractions. A blood-based algorithm for detecting AD in
serum will likely not be the same as one in plasma. In fact,
only a single study to date has published a proteomic profile
that was accurate in detecting AD in both serum and plasma
[18]. Importantly, blood fraction must be taken into consid-
eration in studies examining or reviewing the state of the sci-
ence. A review (or meta-analysis) on specific biomarkers
that does not consider blood fraction will likely be highly un-
interpretable. It is likely that an approach that takes into ac-
count both serum and plasmamarkers will be the most robust
and reliable and should be investigated further.
When looking at platforms, the current results demon-
strate that protein concentrations are not consistently
comparable across platforms. This variability emphasizes
Table 2
Mean protein values across blood fraction and assay platform
Marker
MSD RBM
AD Normal control AD Normal control
Serum Plasma Serum Plasma Serum Plasma Serum
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
A2M (pg/mL) 2180,273,262 (488,669,567.0) 2492,412,927 (1281,547,552) 2072,211,091 (592,581,531.2) 2993,631,363 (1715,510,790) 2.2 (4.0) 0.9 (0.2) 1.2 (0.3)
b2M (pg/mL) 2528,759.6 (1061,896.0) 3006,474.7 (1532,558.3) 2313,211.85 (1019,598.5) 3503,494.1 (2082,171.5) 2.4 (0.9) 2.4 (1.0) 2.3 (1.0)
Eotaxin3 (pg/mL) 3.0 (14.7) 1.4 (1.5) 1.9 (3.6) 1.8 (1.6) 128.5 (140.0) 278.7 (219.2) 89.8 (350.5)
FABP (pg/mL) 8401.3 (4402.2) 7757.3 (4809.8) 7751.8 (3296.3) 7480.3 (4514.0) 3.2 (3.8) 5.5 (5.7) 3.2 (4.1)
THPO (pg/mL) 616.4 (205.6) 488.5 (191.4) 564.0 (163.6) 418.2 (163.7) 7.3 (1.5) 2.3 (1.0) 6.0 (1.8)
PPY (pg/mL) 435.0 (539.9) 946.3 (853.7) 302.9 (225.5) 719.6 (664.5) 147.8 (139.6) 265.0 (201.5) 198.3 (196.9)
CRP (pg/mL) 3787.3 (6154.3) 3928.1 (6242.8) 8044.2 (13,846.6) 4326.4 (7052.6) 3.9 (6.3) 3.7 (4.6) 3.3 (4.4)
sTNFR1 (pg/mL) 4239.4 (2291.2) 3466.3 (1357.4) 3807.4 (1270.2) 3262.6 (1248.7)
IL5 (pg/mL) 3.1 (19.6) 12.6 (83.9) 3.8 (18.7) 3.0 (11.4) 6.3 (5.0) 6.4 (2.8) 7.2 (4.7)
IL6 (pg/mL) 13.6 (105.5) 4.8 (5.9) 2.1 (2.1) 4.7 (5.6) 4.2 (3.0)
IL7 (pg/mL) 10.4 (4.3) 4.4 (4.3) 4.9 (2.5) 3.5 (3.5) 80.8 (53.2) 49.2 (36.3) 108.9 (61.7)
IL10 (pg/mL) 8.2 (46.2) 208.1 (1985.9) 29.2 (119.5) 11.4 (41.9) 9.5 (8.2) 10.1 (5.8)
IL18 (pg/mL) 227.8 (109.2) 252.5 (139.6) 242.48 (112.9) 271.3 (166.2) 278.5 (132.6) 243.3 (93.6) 296.4 (164.3)
I309 (pg/mL) 3.4 (2.5) 2.5 (1.5) 2.8 (2.2) 2.2 (1.5) 265.5 (508.6) 766.0 (1890.0) 585.7 (2241.8)
Factor VII (pg/mL) 898,400.6 (253,545.6) 1282,175.0 (866,370.5) 832,189.1 (221,072.9) 1710,329.8 (1237,574.5) 565.2 (198.5) 591.2 (164.4) 625.4 (226.1)
TARC (pg/mL) 894.3 (608.0) 419.9 (388.2) 761.3 (498.0) 311.2 (468.2)
TNC (pg/mL) 44,085.9 (13,140.6) 56,351.8 (34,425.1) 37,734.3 (10,342.9) 67,010.0 (46,125.5)
TNF-a (pg/mL) 3.4 (3.6) 2.7 (1.0) 1.3 (0.8) 2.8 (1.0) 4.3 (1.7) 9.4 (4.7) 5.2 (4.7)
SAA (pg/mL) 9379.4 (18,741.4) 9351.4 (15,380.3) 7232.6 (21,202.0) 7458.3 (24,674.1)
ICAM1 (pg/mL) 280.7 (64.5) 313.8 (83.5) 321.7 (121.5) 312.4 (67.3) 134.0 (40.4) 107.6 (23.1) 132.8 (33.5)
VCAM1 (pg/mL) 520.7 (121.5) 582.6 (189.3) 482.5 (130.8) 567.3 (132.1) 831.3 (212.6) 772.2 (173.6) 769.9 (209.8)
Abbreviations: MSD, Meso Scale Discovery; RBM, Rules Based Medicine; AD, Alzheimer’s disease; SD, standard deviation; b2M, beta 2 microglobulin; FABP, fatty acid-binding protein; PPY, pancreatic
polypeptide; sTNFR1, soluble tumor necrosis factor receptor 1; IL, interleukin; TARC, thymus and activation-regulated chemokine; TNC, tenascin C; TNF-a, tumor necrosis factor-alpha; SAA, serum amyloid A;
ICAM1, intercellular cell-adhesion molecule-1; VCAM1, vascular cell adhesion molecule-1.
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Table 3
Correlations between serum and plasma markers
Marker R2 P value
SAA 0.99 ,.001
IL10 0.95 ,.001
FABP 0.94 ,.001
I309 0.94 ,.001
IL5 0.94 ,.001
IL6 0.94 ,.001
Eotaxin3 0.91 ,.001
IL18 0.87 ,.001
sTNFR1 0.85 ,.001
PPY 0.81 ,.001
CRP 0.66 ,.001
THPO 0.66 ,.001
sVCAM1 0.65 ,.001
b2M 0.56 ,.001
TARC 0.53 ,.001
A2M 0.45 ,.001
TNF-a 0.44 ,.001
sICAM 0.43 ,.001
IL7 0.36 ,.001
FVII 0.35 ,.001
TNC 0.08 ..05
Abbreviations: SAA, serum amyloid A; IL, interleukin; FABP, fatty acid-
binding protein; sTNFR1, soluble tumor necrosis factor receptor 1; PPY,
pancreatic polypeptide; b2M, beta 2 microglobulin; TARC, thymus and
activation-regulated chemokine; TNF-a, tumor necrosis factor-alpha;
FVII, factor VII; TNC, tenascin C.
Table 4
Random forest variable importance and diagnostic accuracy for detecting
AD with proteomic profile
MSD Serum [19] MSD Plasma [19] RBM Serum [14]
AUC 0.96 AUC 0.76 AUC 0.91
SN/SP 0.91/0.86 SN/SP 0.65/0.79 SN/SP 0.80/0.90
Rank Marker Rank Marker Rank Marker
1 IL7* 1 Eotaxin3 1 Thrombopoietin
2 TNF-a* 2 PPY 2 MIP1a
3 IL5 3 IL7 3 Eotaxin3
4 IL6 4 IL6 4 TNF-a*
5 CRP 5 TPHO 5 Creatine kinase MB
6 IL10 6 b2M 6 FAS ligand
7 TNC 7 sTNFR1 7 Fibrinogen
8 sICAM1 8 FABP 8 IL10
9 FVII 9 TARC 9 IL7*
10 I309 10 IL5 10 CA19-9
Abbreviations: AD, Alzheimer’s disease; MSD, Meso Scale Discovery;
RBM, Rules Based Medicine; AUC, area under the receiver operating char-
acteristic curve; SN, sensitivity; SP, specificity; IL, interleukin; TNF-a, tu-
mor necrosis factor-alpha; PPY, pancreatic polypeptide; MIP1a,
macrophage inflammatory protein 1 alpha; THPO, thrombopoietin; b2M,
beta 2 microglobulin; TNC, tenascin C; sTNFR1, soluble tumor necrosis
factor receptor 1; FABP, fatty acid-binding protein; FVII, factor VII;
TARC, thymus and activation-regulated chemokine CA 19-9, cancer
antigen 19-9.
NOTE. The AUC was calculated using the full 21-protein model [19];
three bolded markers overlap on the MSD platform from serum to plasma.
*Indicates serum markers common across MSD and RBM platforms.
Table 5
Correlation of protein levels across assay platforms
Marker R2 P value
b2M 0.92 ,.001
IL18 0.80 ,.001
FVII 0.78 ,.001
CRP 0.74 ,.001
FABP 0.70 ,.001
sVCAM1 0.69 ,.001
A2M 0.59 ,.001
TNC 0.53 ,.001
sICAM 0.47 ,.001
I309 0.38 ,.001
TNF-a 0.19 .001
THPO 0.17 .004
PPY 0.15 .01
IL7 0.09 .12
IL10 0.01 .89
Eotaxin3 0.01 .89
IL5 20.08 .17
Abbreviations: b2M, beta 2 microglobulin; IL, interleukin; FVII, factor
VII; FABP, fatty acid-binding protein; TNC, tenascin C; TNF-a, tumor ne-
crosis factor-alpha; PPY, pancreatic polypeptide.
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 27-3432the need to cross validate biomarker profiles across plat-
forms in cross-sectional and longitudinal specimens,
particularly those identified on large-scale discovery plat-
forms. A seminal article in this field by Ray et al. [26]
identified a proteomic signature that was highly accurate
in detecting and predicting AD; however, the findings
did not cross validate across platforms [22]. It is unlikely
that a discovery-based platform will demonstrate the
properties, precision, replicability, and accuracy necessary
to become a LDT and, therefore, cross validation on plat-
forms with greater precision is of paramount importance.
One example of a putative biomarker that has been consis-
tently measured across blood fractions and platforms is
that of clusterin (ApoJ). Lovestone and colleagues have
identified an association of clusterin with AD in genetic
studies [27], using proteomics across multiple platforms
[20,21], and within primary neurons [28]. These and other
evolving validation studies can offer novel insights into
the pathobiology of AD and new therapeutic options. Us-
ing a serum-based profile approach, O’Bryant et al.
[14,29] identified an algorithm that was highly accurate
in detecting AD on the Myriad RBM discovery
platform. The algorithm was then cross validated to the
MSD platform (also in serum), and across species
(humans and mouse model) and tissues (serum and brain
microvessels) [19]. Such steps are ultimately necessary
to ensure the confidence in the biomarkers or biomarker
profiles themselves.
There are limitations to the present study. First, the ana-
lyses are cross sectional in nature and, therefore, any links
between blood biomarkers and disease incidence or progres-
sion cannot be assessed. Although the current sample re-
flects a sizable collection of serum- and plasma-based data
from the same individuals at the same blood draw, larger
S.E. O’Bryant et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 3 (2016) 27-34 33samples are needed to validate these findings as well as
examine additional markers and sources of variability. A
study simultaneously examining multiple markers across
multiple assay platforms would be of tremendous value to
the field (across multiple neurodegenerative diseases).
Such a study would allow for the validation of approaches
and markers when used in combination, allow researchers
to optimize specific markers for fit-for-use purposes, as
well as offer a unique opportunity to take a systems biology
approach to understanding neurodegenerative disease-
specific versus overlapping pathologies. Additionally, our
recent work shows that the link between blood-based bio-
markers and disease status (AD vs. controls) and disease out-
comes (i.e. cognition) varies by ethnicity [15,30]. However,
the current findings are from primarily non-Hispanic whites
and may not generalize to other ethnic or racial groups.
Despite these limitations, our findings strongly emphasize
the need to consider blood fraction and assay platform
when interpreting or comparing findings across studies to in-
crease replicability of findings across laboratories and meth-
odologies. Additional work is needed to directly compare
biomarkers across cohorts, blood fractions, assay platforms,
and stages of neurodegenerative disease to push this work
closer to clinical utility.5. Conclusion
The current findings not only point toward a significant
potential source of variability across studies but they also
provide further demonstration of measurement consistency
in select putative AD biomarkers. CRP and PPY have been
consistently touted as key biomarkers for multiple cohorts
[13,14]. It is also important to note that these more robust
markers could, in fact, be contributing to the statistical
significance many of the significant algorithms generated
to date. If the more robust markers can be identified and
validated across blood fractions and assay platforms, these
efforts will most certainly move the field forward.Acknowledgments
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Chasse, PhD.RESEARCH IN CONTEXT
1. Systematic review: A literature review was conduct-
ed to evaluate the current state of the artwork in
blood-based biomarkers of Alzheimer’s disease.
Prior research looking at the accuracy and use of
these markers was reviewed.
2. Interpretation: Potential blood-based biomarkers of
Alzheimer’s disease have received a great deal of
attention in the recent literature. However, little
attention has been focused specifically on factors
limiting the reproducibility of this work.
3. Future directions: This work establishes a clear need
to investigate the comparability of markers across
platforms and blood fractions before comparisons
across studies can be made. Additionally, if “fit-for-
purpose” biomarkers are to be developed, greater
attention must be paid to the preanalytic and analytic
aspects of these studies before any marker will make
it to clinic.
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